Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.
about
Treatment strategies according to genotype for chronic hepatitis B in childrenCurrent antiviral therapy for chronic hepatitis B.End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B.Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patientsMonitoring during and after antiviral therapy for hepatitis B.Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study.High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years.Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B.A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir.
P2860
Q28066476-5792FF09-1C18-467A-9CE2-6C458D840F90Q33631693-41D5B777-F151-4AD5-A866-F16EFE921E14Q36180349-3EC2F946-FE3C-4CBC-B302-9794B2355541Q36391991-D6F6FFD2-CED7-4F34-93A1-138C4267788AQ37186162-7705350C-FEE2-4DEF-804B-749D871658FFQ40526027-63647D4E-D479-432C-8C76-B5E285915387Q42217489-49EF13E5-0265-42AA-B41A-EC312E8224E6Q43245080-FF025160-5760-4A63-9A41-40B7C31B7D68Q44254904-BB469CFE-3804-4FBA-8C14-1882772504D9Q45067577-19880670-AB93-4DB9-B6A1-D6994A5B3412Q45254325-31A16F98-290D-4DDD-BD6F-B4F71E995775
P2860
Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Quantitative polymerase chain ...... ntigen loss or seroconversion.
@ast
Quantitative polymerase chain ...... ntigen loss or seroconversion.
@en
type
label
Quantitative polymerase chain ...... ntigen loss or seroconversion.
@ast
Quantitative polymerase chain ...... ntigen loss or seroconversion.
@en
prefLabel
Quantitative polymerase chain ...... ntigen loss or seroconversion.
@ast
Quantitative polymerase chain ...... ntigen loss or seroconversion.
@en
P2093
P2860
P356
P1433
P1476
Quantitative polymerase chain ...... ntigen loss or seroconversion.
@en
P2093
P2860
P304
P356
10.1136/GUT.52.12.1779
P407
P577
2003-12-01T00:00:00Z